Clinical trials: Healthy Males
Healthy
Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers
Study to investigate the relative bioavailability of ambroxol hydrochloride soft pastilles 15 mg vs. ambroxol hydrochloride (HCL) 15 mg of syrup (15mg/5mL, Reference I) and ambroxol hydrochloride 15 mg of syrup (30mg/5mL…
- Trial name
- NCT02194270
- Testing
- Ambroxol hydrochloride - soft pastille, Ambroxol hydrochloride - syrup - low dose, Ambroxol hydrochloride - syrup - high dose
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Male Volunteers
A Phase I Study to Investigate KH-001 in Healthy Males
This was a Phase I, first-in-human study of KH-001 besylate in healthy male participants, conducted to investigate the safety, tolerability and pharmacokinetics (PK) of the study drug.
- Trial name
- NCT07868237
- Testing
- KH-001 besylate
- Where
- United Kingdom
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Kadence Bio
Type 2 Diabetes Mellitus
A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of…
- Trial name
- NCT02411929
- Testing
- Unlabeled ertugliflozin for oral use, 14^C-labeled ertugliflozin for IV use, 14^C-labeled ertugliflozin for oral use
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Amyotrophic Lateral Sclerosis, Healthy Volunteer
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
This is a Phase 1, cross-over, 2-part study for pharmacokinetic (PK) assessment of SAR443820 when co-administered with cytochrome P450 3A4 (CYP3A4) inhibitors (erythromycin ethyl succinate (EES) in Part A and possibly…
- Trial name
- NCT05797753
- Testing
- SAR443820, Erythromycin ethyl succinate, Itraconazole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sanofi
Parkinson Disease
Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156
The study is designed to determine the absorption, distribution, metabolism and elimination (ADME) of BIA 28-6156 in humans, further explore the PK of BIA 28-6156, evaluate the extent of distribution of total radioactivity into…
- Trial name
- NCT05220072
- Testing
- Carbon-14 BIA 28-6156
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bial R&D Investments, S.A.
Healthy
A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine
To investigate the effect of BI 474121 compared to placebo on ketamine-induced cognitive deficits to predict efficacy in patients with cognitive disorders.
- Trial name
- NCT05451095
- Testing
- BI 474121, Ketamine hydrochloride
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Japanese Healthy Adult Males
A Bioequivalence Study of TAK-536 Pediatric Formulation
The purpose of this study is to evaluate the bioequivalence of a single oral dose of 2 different drug forms of TAK-536 pediatric formulation and a single oral dose of TAK-536 commercial tablet in healthy Japanese adult male…
- Trial name
- NCT02401464
- Testing
- TAK-536 Tablet, TAK-536 Dry Syrup Formulation, TAK-536 Ganule Formulation
- Where
- Japan
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Takeda
Insomnia
A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
The purpose of this study is to investigate and evaluate the bioequivalence and food effect of SEP 190-102 in Japanese healthy subjects by assessing the pharmacokinetics parameters.
- Trial name
- NCT01055834
- Testing
- Eszopiclone 3 mg, Eszopiclone 1 mg
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Healthy
A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood
The main objective of this trial is to investigate: the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs.
- Trial name
- NCT06193811
- Testing
- Avenciguat (BI 685509) (intended commercial formulation (iCF)), Avenciguat (BI 685509) (trial formulation 2 (TF2)), esomeprazole
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM
- Trial name
- NCT03646721
- Testing
- DA-1241, Sitagliptin
- Where
- 4 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Erectile Dysfunction
Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects
It is a single-center, open-label, Phase I clinical study evaluating the safety and pharmacokinetics of a single oral TPN171H in elderly subjects.
- Trial name
- NCT06090136
- Testing
- TPN171H
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers
First evaluation of safety, tolerability, pharmacokinetics and the pharmacodynamic effect of BI 11634 on coagulation parameters
- Trial name
- NCT02214914
- Testing
- BI 11634 drinking solution, BI 11634 tablet
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Infection, Human Immunodeficiency Virus, HIV Infections
Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment
GSK1265744 (744) is an integrase strand transfer inhibitor (INSTI) currently in development for both the treatment and prevention of human immunodeficiency virus (HIV) infection.
- Trial name
- NCT02354937
- Testing
- GSK1265744 30 mg
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- ViiV Healthcare
Schizophrenia
A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose
The purposes of this study are to investigate the metabolic pathways of paliperidone and excretion of paliperidone and its metabolites in healthy adult male volunteers, both CYP2D6 poor and extensive metabolizers, after…
- Trial name
- NCT00796029
- Testing
- 14C-paliperidone
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers
The purpose of this study is to compare the drug interaction of pharmacokinetics of rosuvastatin and ezetimibe.
- Trial name
- NVP-1205 (NCT02289430)
- Testing
- Crestor+Ezetrol, Ezetrol, Crestor
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- NVP Healthcare
Healthy
A Study in Healthy People to Test How Vicadrostat Affects the Heart
The main objective of this trial is to investigate the effect of vicadrostat on the heart compared with placebo in healthy male and female volunteers.
- Trial name
- NCT07513207
- Testing
- Vicadrostat, Moxifloxacin
- Where
- Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Immunosuppression For Disease
Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020
The purpose of this study is to assess the pharmacokinetics (PK), metabolism, routes and extent of elimination, as well as safety and tolerability of a single oral solution dose of [14C] Bristol-Myers Squibb (BMS)-986020 in…
- Trial name
- NCT02068053
- Testing
- [14C] BMS-986020
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants
The primary purpose of the study is to determine the mass balance of total radioactivity and the routes of elimination by quantifying the urinary and fecal excretion of radioactivity following a single oral administration of…
- Trial name
- NCT05652257
- Testing
- [14C]-brensocatib
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Insmed Incorporated
Healthy
Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532
The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of [14C]PF-04991532 in healthy adult male subjects.
- Trial name
- NCT01469481
- Testing
- PF-04991532
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Health Adult Subjects
Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®
The study is being conducted to compare the pharmacokinetic (PK) parameters of HLX319 and EU-Phesgo® after a single subcutaneous administration in healthy male subjects in China, providing a basis for the design of subsequent…
- Trial name
- NCT07495930
- Testing
- HLX319, EU-Phesgo
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.